Patent · US Active

2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors

US9428508B2 · kind B2 · utility

1Cited by

0References

3Claims

0Family size

Assignee

CENTAURUS BIOPHARMA CO., LTD. · CN

Inventors

Dengming Xiao · Longmont, US
Liang Cheng · Beijing, CN
Xijie Liu · Beijing, CN
Yuandong Hu · Beijing, CN
Xinhe Xu · Beijing, CN
Zhihua Liu · Beijing, CN
Lipeng Zhang · Shanghai, CN
Wei Wu · Qingdao, CN
Shulong Wang · Beijing, CN
Yu Shen · Beijing, CN
Gen Li · Beijing, CN
Yin Wang · Beijing, CN
Sheng Zhao · Qingdao, CN
Chonglong Li · Beijing, CN
Jia Xing Tang · Beijing, CN
Honghao Yu · Beijing, CN

Key dates

Filing date	Jan 7, 2012
Grant date	Aug 30, 2016
Priority date	—
Expiry date	Jan 7, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D493/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.